Phase 4
Completed N=29
A Study to Evaluate Pneumococcal Polysaccharide Vaccine Effectiveness in Children With Type 1 Diabetes
Source: ClinicalTrials.gov NCT04481243 ↗Enrolled (actual)
29
Serious AEs
0.0%
Results posted
Nov 2023
Primary outcomePrimary: Immunoglobulin G (IgG) Antibodies — 270.0 mcg/mL
◆ Published Evidence
Emerging
1citation · ~1 / year
Seroconversion following PPSV23 vaccination in children with type 1 diabetes mellitus.
Summary
The purpose of this study is to determine if children with type 1 diabetes have adequate immune response to PPSV23 vaccination and to assess factors affecting immune response.
Linked Publications
-
Seroconversion following PPSV23 vaccination in children with type 1 diabetes mellitus.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Immunoglobulin G (IgG) Antibodies |
270.0 | — |
Eligibility Criteria
Inclusion Criteria
- Children ages 3-18 years old.
- Clinical diagnosis of Type 1 diabetes.
Exclusion Criteria
- Newly diagnosed with Type 1 diabetes with in the past month of study date.
- Contraindications to receiving 23 valent pneumococcal vaccines.
- Other conditions associated with compromised immunity and vaccine response.
- Primary or Secondary Immune deficiency.
- Previous receipt of PPSV-23 vaccination.
Data sourced from ClinicalTrials.gov (NCT04481243) and the linked publication. Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.